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Summary. The synthesis of diastereoisomeric [1,2-bis 
(2-hydroxyphenyl)ethylenediamine]dichloroplatinum(II) 
complexes, DL-3-PtC12 and meso-3-PtC12, and their eval- 
uation on the hormone-independent, human MDA-  
MB231 breast cancer cell line, on the cisplatin-sensitive 
and -resistant L1210 leukemia cell line, on the cisplatin- 
resistant human NIH:OVCAR 3 ovarian cancer cell line, 
on the P-388 leukemia of the mouse and on the cisplatin- 
sensitive and -resistant Ehrlich ascites tumor of the 
mouse are described. On all tumor models DL-3-PtC12 
produces amarked inhibitory effect. The diastereoisomer 
meso-3-PtClz  is less active and more toxic. It is striking 
that DL-3-PtC12 leads to a pronounced inhibition of all 
cisplatin-resistant tumors. At non-toxic concentrations 
DL-3-PtC12 produces cytocidal effects on the NIH:OV- 
CAR 3 cell line. Therefore DL-3-PtC12 is of interest for 
further evaluation for the therapy of ovarian cancer. 
Key words: [DL-1,2-Bis(2-hydroxyphenyl)ethylenedia- 
mine]dichloroplatinum(II) - Ovarian cancer 
Introduction 
The first communication on the capability of cisplatin to 
initiate regression in advanced ovarian cancer was made 
by Wiltshaw and Cart (1974; see also Barker 1983). Cis- 
platin produces a therapeutic response ven in patients 
with refractory ovarian carcinoma (Wiltshaw and 
Kroner 1976). In high dosage cisplatin leads to response 
rates up to 63% and in some cases to complete remissions 
(18%) with a survival time greater than 2 years in several 
of these patients (Barker and Pring 1981; compare Ozols 
et al. 1985; Ozols and Young 1985; Eisenhauer et al. 
1986). 
The reason for the short overall survival time is the 
rapid development of resistance in ovarian tumor cells 
(Ozols and Young 1984, compare also Bruntsch 1985; 
Offprint requests to." H. Sch6nenberger 
Weiss 1986). Cisplatin-resistant tumor cells show mul- 
tiple biochemical differences in comparison to the related 
sensitive cells, e.g. a reduced capability to accumulate cis- 
platin, an increased intracellular level of glutathione and 
an enhanced DNA repair, i.e. cisplatin-nucleoside-ad- 
duct removal (see Lai et al. 1988 for references). 
The Sonderforschungsbereich 234has been working 
for some time on the development of platinum complexes 
that show an activity on cisplatin-resistant tumor models. 
Such compounds are of interest: (a) in combination with 
cisplatin for first-line treatment of ovarian cancer to 
avoid or retard the development of resistance; (b) for the 
second-line therapy of ovarian cancer after development 
of resistance against cisplatin. 
In recent publications (Wappes et al. 1984; Jenner- 
wein et al. 1989 a, b) we have shown that stereoisomeric 
dichloro(1,2-diphenylethylenediamine)platinum(II) 
complexes with hydroxy groups in the 3 or 4 positions of 
both benzene rings (Scheme 1, compounds 1-PtC12 and 
2-PtCI2) possess a marked activity on the Ehrlich ascites 
tumor of the mouse. On the cisplatin-resistant variant of 
this tumor, however, only the 3-hydroxy derivatives (2- 
PtCI2) lead to an inhibition of tumor growth (Jennerwein 
et al. 1989b). Their effect was most outstanding in the 
case of the compound with R,R/S ,S  configuration 1,
which produced 40% cures at a dose of 3 x 2.5 mg/kg, i.p. 
1 R,R/S,S = racemate = DL; R,S = meso 
X - -~ ' ]  ~-~ X Compound X 
-1-PtCI 2 Q-OH 
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H2N~ /H2 -3-PtCI 2 2-OH 
Cl Cl 
N• / NH3 /P t  CisPlotin 
c1 c1 Scheme 1 
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(days 1-3). The combination of compound 2-PtC12 (S,S 
configuration) with cisplatin results in a weakly synergis- 
tic effect in cell culture experiments using the hormone- 
independent human MDA-MB231 breast cancer cell line 
(Jennerwein et al. 1989 b). 
To our surprise, the shift of both OH groups of the 
R,R/S,S compound 2-PtC12 from the 3 into the 2 position 
(compound DL-3-PtCI2) produces a distinct elevation of 
antitumor activity on the cisplatin-resistant Ehrlich as- 
cites tumor (Scheme 1). 
This publication will report on the synthesis of the 
two diastereoisomeric [1,2-bis(2-hydroxyphenyl)ethyl- 
enediamine]dichloroplatinum(II) compounds (DL-3- 
PtC12 and meso-3-PtC12) and their antitumor activity on 
several tumor models. 
Materials and methods 
Chemistry. meso-l,2-Bis(2-hydroxyphenyl-ethylenediamine (meso- 
3), originally described by Japp and Hooker (1884), was synthesized 
from salicylic aldehyde and ammonia using an improved method 
published by V6gtle and Goldschmitt (1976). N,N'-Disalicylidene- 
meso-l,2-bis(2-methoxyphenyl)ethylenediamine (meso-3c) was syn- 
thesized by the stereospecific [3.3] sigmatropic diaza-Cope rear- 
rangement reaction according to the method of V6gtle and 
Goldschmitt (1976) from meso- 1,2-bis(2-hydroxyphenyl)ethylenedi- 
amine (meso-3) and 2-methoxybenzaldehyde in boiling CH3CN 
(Scheme 2, method A). Upon hydrolysis with 3M H2SO4 meso-1,2- 
bis(2-methoxyphenyl)ethylenediamine (meso-3a) was obtained 
(Scheme 2, method B). The reaction ofmeso-3a with 2-methoxyben- 
zaldehyde led to the symmetrical diimine meso-3b (Scheme 2, 
method C). The compound meso-3b was melted. At temperatures 
higher than 120 ~ C there is equilibrium bctween the diimines meso- 
3b and DL-3b. The diastereoisomeric products were separated by 
their different solubility in CH2C12 (Scheme 2, method D). OL-1,2- 
Bis(2-methoxyphenyl)ethylenediamine (OL-3a) was prepared by hy- 
drolysis Of DL-3b in 3M HzSO4 (Scheme 2, method E). DL-1,2-Bis(2- 
hydroxyphenyl)ethylenediamine (DL-3) was obtained by ether cleav- 
age ofoL-3a (Scheme 2, method F). It was difficult o find an appro- 
priate method for this reaction. Various ether cleavages with BBr3/ 
CHzC1 z abs., HBr, HI and BBr3/boiling CHC13 abs. were tested, 
and the best results eemed to be achieved by using BBr 3 in CHzC12 
at room temperature for 3 days. Trials to purify DL-3 further caused 
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its decomposition a d were avoided. [DL-l,2iBis(2ihydroxyphenyl)- 
ethylenediamine]dichloroplatinum(II) (DL-3-PtC12) was synthesized 
by reaction of DL-1,2-bis(2-hydroxyphenyl)ethylenediamine (DE-3) 
with K2PtC14 (Scheme 3, method G). For steric reasons the com- 
plexation of meso ligands proceeds very slowly. Therefore faster 
complexation was achieved with the reaction of K2PtI 4 and meso- 
1,2-bis(2-hydroxyphenyl)ethylenediamine (meso-3) (Scheme 3, 
method H). To exchange iodine for chlorine, I -  was precipitated 
with Ag2SO 4 and subsequently the intermediate di-aqua complex 
was converted to the dichloro complex (meso-3-PtC12) by addition 
of KCI (Scheme 3, method I). The purity of the platinum com- 
pounds was confirmed by elemental analysis (Table 1) and HPLC 
(Table 4). The infrared and 1H-NMR data (Table 2) "are in good 
agreement with former results. In the phenolic ligands (meso-3 and 
DE-3) the hydroxy and the amine protons appear as one signal 
(Table 2). After complexation the peaks for OH and NH 2 are sep- 
arated. 
meso -N,N'-Disalicylidene- 1,2-bis (2-methoxyphenyl) ethylenedi- 
amine (meso-3c) method A. meso-l,2-Bis(2-hydroxyphenyl)ethyl- 
enediamine (meso-3, 47,52 g=0A95 tool) and 2-methoxybenzalde- 
hyde (52.97 g = 0.389 tool) are refluxed in 300 ml MeCN for 3 h. 
The solution is concentrated to 150 ml. After standing in the refrig- 
erator ffir I h the precipitate iscollected in a Buchner funnel, washed 
with small amounts of ice-cold MeCN and dried over P205. Yield: 
92%; yellow powder, rap: 211~ ~ C. 
meso- l,2-Bis ( 2-methoxyphenyl )ethylenediamine (meso-3a) method 
B. Meso-3c (77.52 g=0.161 tool) is hydrolyzed with 700 ml 
3M H2SO~ and the salicylic aldehyde formed is removed by steam 
distillation. The hot solution is filtered and made alkaline with 20% 
NaOH under vigorous tirring and cooling by ice. The diamine is ex- 
tracted with CH2C12 and the organic phase is dried over MgSO 4. 
The solvent is removed under reduced pressure and the residue is 
dried over P205 . Yield: 89%; colorless olid, rap: 75o-76 ~ C. 
meso-N,N'-Bis ( 2-methoxybenzylidene ) - 1,2-bis (2-methoxyphenyl)- 
ethylenediamine (meso-3b) method C. meso-3a (37.36 g = 
0.137 mol) is treated as described in method A. Yield: 81%; color- 
less powder, rap: 215~ ~ C. 
DL- N,N'-Bis (2-metho xybenzylidene )- l,2-bis (2-methoxyphen yl)-
ethylenediamine (DL-3b) method D. meso-3b (56.38 g = 0.111 mol) 
is melted under vigorous tirring. After 10 rain the liquid is allowed 
to cool. The glassy mass is stirred with 250 ml CH2CI 2 for 16 h. The 
precipitate ( = meso-3b) iscollected in a Buchner funnel and the sol- 
vent is removed from the filtrate under vacuum. The residue (DL-3b) 
is dried over PzOs. Yield: 51% meso-3b, 44% DL-3b; yellow powder, 
mp: 165 168 ~ 
DL-1,2-Bis(2-methoxyphenyl)ethylenediamine (DL-3a) method E. 
DL-3b is hydrolyzed in the same manner as described in method B. 
Yield: 90%; brown oil. 
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DL-1,2-Bis(2-hydroxyphenyl)ethylenediamine DL-3) method F. A so- 
lution of DL-3a (3.00 g -- 11.02 mmol) in 150 ml CH2CI z abs. is 
cooled under stirring to --60 ~ C. BBr3 (11.04 g = 44.07 mmol) is 
added slowly with a syringe. The reaction mixture is stirred for 
30 rain at - 60 ~ C and for 3 further days at room temperature, then 
50 ml CH3OH are added slowly under cooling and the solvent is re- 
moved under reduced pressure at 30" C. This procedure is repeated 
twice. The residue is dissolved in 50 ml H20. The solution is filtered 
through a no. 3 fritted glass filter. The product is precipitated from 
the filtrate with 20% NaOH at pH 9 11 under cooling. The reaction 
mixture is extracted with ethyl acetate. The organic layer is dried 
over MgSO4. After filtration the organic layer is removed under re- 
duced pressure at 30 ~ C and the residue is dried over  P205 . Yield: 
75%; orange glassy mass. 
/DL- 1,2- Bis ( 2-hydroxyphenyl) e thylenediamine ] dichloroplatinum- 
(I1) DL-3-PtCI2) method G. An aqueous solution of K2PtC14 
(322 mg= 0.78 mmol in 10 ml) is added slowly to a solution Of DL-3 
(190 mg = 0.78 mmol in 10 ml H20 and 2 ml 2M HC1). The mix- 
ture is stirred in the dark at room temperature. The pH is kept at 
2.5-3.5 for 2 days and at 5.5-6.5 for 3 further days. The complex is 
collected in a no. 3 fritted glass filter and washed three times with 
I M HC1, and three times with water and dried under vacuum over 
silica gel/CaCl 2 at 80 '~ C. Yield: 78%; yellow powder. 
/meso- 1,2-Bis (2-hydroxyphenyl) ethylenediamine]diiodoplatinum (I1) 
(meso-3-Ptlz) method H. An aqueous solution of KzPtC14 
(1.7 g = 4.09 mmol in 40 ml water) and KI[13.61 g = 82 mmol) is 
stirred for 30min at room temperature, meso-3 (1.00g = 
4.09 mmol) is dissolved in 40 ml water at 40 ~ C by adding 2 M HC1 
dropwise. The dark KzPtI 4 solution is added slowly to the ligand so- 
lution. The reaction mixture is stirred for 24 h at room temperature 
in the dark. The pH is kept between 5.5 and 6.5. The complex is col- 
lected in a no. 3 fritted glass filter and washed three times with 2 M 
HC1 and three times with water and dried under vacuum over silica 
gel/CaC12 at 80 ~ C. Yield: 67%; yellow powder. 
[meso- l,2-Bis ( 2-hydr oxyphenyl ) ethylenediamine ] dichlor oplatinum 
(11) (meso-3-PtCl2) method L meso-3-PtI2 (504 rag=0.73 rnmol) 
and AgzSO4 (227 mg= 0.79 mmol) are stirred for 5 days at room 
temperature in the dark. The precipitated AgI is filtered off with a 
no. 4 fritted glass filter. KC1 (1.09 g = 14.6 mmol) is added to the 
filtrate. After 1 day of stirring at room temperature the product is 
collected in a no. 3 fritted glass filter, washed three times with 1 M 
HC1 and water and dried over silica gel/CaC1 zat 80 ~ C. Yield: 35 %; 
yellow powder. 
General procedures. Melting points (uncorrected) were deter- 
mined on a Bfichi 510 melting point apparatus; for 1H-NMR spectra 
of the ligands a Varian EM 360-L 60-MHz spectrometer was used 
and the tH-NMR spectra of the platinum complexes were received 
on a Bruker PFR-NMR spectrometer WM 250 at 250 MHz. 
Elemental analyses were performed by the microlaboratory of the 
University of Regensburg. For the HPLC (Altex model 420; 
pump: Altex model 110 A; Cls-reversed phase column, Merck, 
Lichrosorb), Img platinum complex dissolved in 1 ml methanol is 
eluted with the solvent system: 60% methanol (Merck Lichrosolv)/ 
40% bidistilled water, and assayed at 276 nm (Uvikon 720 LC 
spectrometer). 
Biological methods 
MDA-MB231 human breast cancer cell line. The MDA-MB231 cell 
line (Lippman et al. 1977) was kindly provided by Dr. M.E. Lipp- 
man, NCI, Bethesda, USA. Cells were grown in a humified incuba- 
tor in 5% CO2, at 37 ~ C. McCoy 5a medium, supplemented with 
gentamicin (40 gg/ml), 10% newborn calf serum, and NaHCO3 
(11 g/5 1) was used as culture medium. The cells were harvested with 
trypsin/EDTA, diluted with medium containing 5% newborn calf 
serum, and syringed gently to prevent clumping. Approximately 
2 x 104 cells in 2 ml were plated in duplicate in 6-well dishes (Co- 
star). Then 2 days later the medium was changed and the Pt com- 
plexes were added as freshly prepared 1000-fold concentrated solu- 
tions in dimethylformamide, leading to a final solvent concentration 
of 0.1%. The cells of control wells contained an equal volume of di- 
methylformamide. After an incubation time of 2 days, which com- 
plied with a triple duplication time, the cells were labeled with 1 gCi 
[3H]thymidine/well for 2 h. Cells were washed with ice-cold phos- 
phate-buffered saline (PBS) and harvested with PBS/EDTA buffer. 
After centrifugation, the cell pellet was resuspended in I ml PBS and 
divided into two 0.5-ml aliquots. One part was counted in a ZI 
Coulter counter, the other was sonicated. After addition of 4 mt 
10% trichloroacetic acid, the acid-insoluble fraction was collected 
on a 0.45-gm filter (Metricel, Gelman) and counted, after addition 
of 10ml scintillation liquid (LS 8000 Beckman scintillation 
counter). 
The [3H]thymidine was obtained from New England Nuclear, 
Dreieich, FRG, the newborn calf serum from Biochrom, Berlin, the 
McCoy 5a medium and the trypsin (0.05%)/EDTA (0.02%) solu- 
tion from Boehringer, Mannheim, FRG, and the scintillation liquid 
Quickszint 212 from Zinsser, Frankfurt, FRG. The PBS contained 
NaC1 (8 g), KC1 (0.2 g), NazHPO 4- 2H20 (1 g), NaHzPO 4. HzO 
(0.15 g), and KH2PO4 (0.2 g) in 1 1 HzO.  TO prepare PBS/EDTA 
buffer 0.02% EDTA was added to the PBS. 
NIH:OVCAR-3 ovarian cancer cell line. The NIH:OVCAR-3 
(ATCC no. HTB 161), a human adenocarcinoma of the ovary 
(Hamilton et al. 1983), was obtained from the American Type Cul- 
ture Collection in passage 17. Cell-line banking and quality control 
were performed according to the "seed stock concept" reviewed by 
Hay (1988). The cells were maintained in RPMI-1640 (Sigma) con- 
taining NaHCO3 (2 g/l), gentamicin (50 nag/l), 10% BMS 
(Seromed) and insulin (10 pg/ml) (Sigma) in 75-cm z flasks at 37 ~ C 
Table 1. [l,2-Bis(2-hydroxyphenyl)ethylenediamine]dihaloplati- 
num(II) complexes: analytical data 
Compound C (%) H (%) (H%) 
Calc. Found Calc. Found Catc. Found 
meso-3-PtI 2 24.3 24.1 2.33 2.42 4.0 3.9 
meso-3-PtC12 33.0 32.9 3.16 3.31 5.5 5.4 
DL-3-PtC12 33.0 33.0 3.16 3.24 5.5 5.0 
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Table 2. 1H-NMR data of [1,2-bis-(2-hydroxyphenyl)ethylenediamine]dihaloplatinum(II) complexes (250 MHz, dimethylformamide-dv) and 
of their ligands (60 MHz, CDC13; Me3Siint) 
Compound 6 (ppm) 
Aromatic H CH benzyl NH OH OCH 3 
meso-3 6.75-7.30 (m, 8H) 4.28 (s, 2H) 4.72 (s, br,6H) 
meso-3a 6.78-7.56 (m, 8H) 4.54 (s, 2H) 1.88 (s, 4H) 
DL-3a 6.74~7.60 (m, 8H) 4.52 (s, 2H) 1.85 (s, 4H) 
OL-3 6.667.51 (m, 8H) 4.26 (s, 2H) 5.56 (s, br, 6H) 
meso-3-PtI2 6.67-6.73 (m, 4H) 4.80 (br, 2H) 5.13 (br, 2H) 9.49 (s, 2H) 
7.01-7.08 (m, 2H) 6.07 (br, 2H) 
8.09-8.12 (m, 2H) 
meso-3-PtCl z 6.68-6.73 (m, 4H) 4.83 (br, 2H) 5.25 (br, 2H) 9.50 (s, 2H) 
7.01-7.07 (m, 2H) 6.12 (br, 2H) 
8.16-8.19 (m, 2H) 
DL-3-PtC12 6.57 6.63 (m, 2H) 4.71 (br, 2H) 5.27 (br, 2H) 10.56 (s, 2H) 
6.86-6.89 (m, 2H) 6.10 (br, 2H) 
7.01 7.07 (m,4H) 
3.73 (s, 6H) 
3.84 (s, 6H) 
Table 3. 1H-NMR of N,N'-dibenzylidene- 
1,2-diphenylethylenediamines 
(60 MHz, CDC13; Me3Sii,t) 
Compound ~ (ppm) 
Aromatic H CH benzyl N = C-H  OCH 3 
meso-3c 6.52-7.58 (m, 16H) 5.45 (s, 2H) 8.20 (s, 2H) 3.61 (s, 6H) 
meso-3b 6.66-8.33 (m, 16H) 5.44 (s, 2H) 8.85 (s, 2H) 3.64 (s, 6H) 
3.80 (s, 6H) 
DL-3b 6.54~8.29 (m, 16H) 5.54 (s, 2H) 8.84 (s, 2H) 3.53 (s, 6H) 
3.64 (s, 6H) 
Table 4. HPLC analysis of the platinum complexes 3" 
Compound tR (min) 
DL-3-PtC12 4.8 
meso-3-PtI 2 3.8 
meso-3-PtC12 3.0 
a All compounds eluted as single peaks 
in a HzO-saturated atmosphere of 95% air and 5% CO2. The cells 
were serially passaged weekly following trypsinization using tryp- 
sin/EDYA (Boehringer). 
For chemosensitivity testing the cells (in passage 30) were plated 
in 96-well microplates (100 gl/well) at a density of about 19 cells/ 
microscopic field (Leitz Diavert, 320 x ) and were allowed to attach. 
After 73.5 h, the medium was removed by suction and replaced with 
fresh medium (200 gl/well) containing drug (drugs were added as a 
1000-fold stock solution in dimethylformamide) or pure solvent. On 
every plate the rows 5 and 6 (n = 16) acted as controls, whereas two 
vertical rows (n = 16) per drug concentration and time point were 
used. After varying times of incubation the cells were fixed with glu- 
taraldehyde and stored under PBS at 4 ~ C. All plates were stained 
with crystal violet simultaneously. The processing procedure and 
data analysis were performed as described by Reile et al. (1989). 
Drug effects were calculated as corrected TIC values according to: 
T/Ccorr = (T-- Co)/(C- Co) where Tis the absorbance of treated cells, 
C the absorbance of the controls and Co the absorbance at the time 
(t=0) when drug was added. The experimental errors for T/Ccorr 
range from approximately _+20% after short times of incubation 
(small values for AT and AC compared to Co) to +5% with pro- 
longed incubation. 
L1210 leukemia cell line ( a ) (experiments concerning Fig. 7). The cy- 
totoxicity of platinum compounds was determined by cloning cells 
of the L1210 murine leukemia or of its subline L1210/Pt (25-fold re- 
sistant) in soft agar. Treatments were for 1 h at 37 ~ C in the presence 
of 10% fetal calf serum (Seromed, Biochrom company). Cells were 
not washed before cloning in soft agar since the medium was diluted 
1 : 400 during this procedure. Cells were then plated in 30-mm petri 
dishes (Falcon) and incubated for 7 days in 5% 02, 5% CO2 and 
90% N2. The final concentration of fetal calf serum was 20% in soft 
agar (Bacto Agar, Difco). Colonies (> 50 cells) were scored by in- 
spection of petri dishes on an inverted Leitz microscope and frac- 
tional survival was plotted semilogarithmically. Cisplatin (Platinex, 
Bristol Myers company) was available as a stock solution in physi- 
ological saline and diluted appropriately with RPMI-1640 medium 
supplemented with 10% fetal calf serum. Compounds meso-3-PtC12 
and DL-3-PtC12 were provided as crystalline white powders and were 
made up as stock solutions of 5.1 mg/ml with dimethylsulfoxide. 
Drug resistance to cisplatin was induced by intermittent exposures 
of L1210 cells to increments of 0.2 p.g/ml of the drug in tissue culture 
if the cell doubling time during exposure and in the subsequent pas- 
sage without drug was no more than 2-3 days. A total of 78 passages 
over 15 months were necessary to achieve the level of resistance 
found in the present experiment. During this time concentrations of 
cisplatin in the medium were increased from 0.1 gg/ml to 10 gg/ml. 
L1210 leukemia cell line (b) (experiments concerning Table 7). Sen- 
sitive and resistant L1210 cells have been developed and described 
by Eastman and Illenye (1984) and by Richon et al. (1987). Suspen- 
sion cultures are grown in McCoy's 5a (modified) medium supple- 
mented with NaHCO3 (2.2 g/l), penicillin (250 U/ml), streptomycin 
(250 U/ml), fungizone (1 gg/ml) and 16% calf serum. For growth 
inhibition 4 ml cell suspension (approximately 5 x 10 4 cells/ml) was 
incubated in triplicate with varying concentrations of drug over a 3- 
day period. The drug was added as a 1000-fold stock solution in di- 
methylformamide or dimethylsulfoxide. Stock solutions, especially 
dimethylsulfoxide solutions, were kept no longer than 5 10 min. 
After 3 days l-ml aliquots were counted on a Coulter counter. 
P388 leukemia. The P388 leukemia (Dawe and Potter 1957; Geran 
et al. 1972) was maintained by routine passage in female DBA/2 
mice (ivanovas, Kisslegg, FRG). For determination of antitumor 
activity, female CDF 1 mice (18-22 g, Zentralinstitut f/Jr Versuchstie- 
re, Hannover, FRG) were inoculated i.p. with 106 leukemia cells in 
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0.1 ml PBS buffer (day 0). The animals were assigned randomly to 
groups of six (ten animals to the solvent control) and the complexes 
were administered i.p. on days 1, 5, and 9 or 1o9 as a solution in 
polyethylene glycol 400/1.8% NaC1 in H20 (1 : 1). The antitumor 
activity was evaluated as the median survival time (days) compared 
to the untreated control. 
Ehrlich ascites tumor. A hyperdiploid Ehrlich ascites tumor (ETwT) 
was maintained by weekly transplantation f 2.5 x 10 7 tumor cells 
into female random-bred NMRI mice, as has been described earlier 
(Seeber et al. 1982). Tumor lines with documented in vivo resistance 
towards daunorubicin, doxorubicin, etoposide, cisplatin, 4-hy- 
droxycyclophosphamide and also towards a combination of dox- 
orubicin and cisplatin were developed by biweekly i.p. injections of 
increasing doses of the drugs as described (Seeber et al. 1982; Seeber 
1982). In order to maintain a > 32-fold anthracycline r sistance, a 
> 8-fold etoposide resistance and a > 4-fold cisplatin resistance the 
tumor lines were intermittently exposed to the drugs in vivo using 
5 mg/kg daunorubicin, 12 mg/kg etoposide and 8 mg/kg cisplatin at 
2- to 4-week intervals. For comparative analyses of the in vivo activ- 
ities of cisplatin and the platinum complexes groups of ten animals 
were formed and 2.5 x 10 7 tumor cells were inoculated i.p. The 
drugs to be tested were injected i.p. 24 h later on days 1, 2, 3 as a 
solution in polyethylene glycol 400/1.8% NaC1 (1 : I). All animals 
were followed for survival for at least 30 days. 
Results and discussion 
The diastereoisomeric [1,2-bis(2-hydroxyphenyl)ethyl- 
enediamine]-dichloroplatinum(II) complexes DL-3-PtC12 
and meso-3-PtC12 were tested on the hormone-indepen- 
dent, human MDA-MB231 breast cancer cell line 
(Table 5). DL-3-PtC12 shows a significantly stronger in- 
hibitory effect on [3H]thymidine incorporation and cell 
growth than its diastereoisomer meso-3-PtC12. The anti- 
tumor activity of  DL-3-PtC1 z is one-third that of  cis- 
platin. 
For testing the activity of  DL-3-PtC12, meso-3-PtC12 
and cisplatin against ovarian cancer the N IH :OVCAR-3  
cell line was used. Hamilton et al. (1983) have described 
this cell line to be resistant o clinically relevant concen- 
trations of  Adriamycin, melphalan and cisplatin. 
In order to provide the most information, the data are 
presented as growth curves (absorbance plotted versus 
time of  drug exposure) as well as correced TIC values ver- 
sus time of  drug exposure. A gradual decrease of  TIC .... 
values with time indicates an inhibition of  cell growth (i.e. 
a slowing down or a stopping of  cell proliferation = cy- 
tostatic drug action). No  change or increase of  T/Ccorr 
values with time of  drug exposure represents primary 
drug resistance or recovery of  the cells f rom drug-induced 
damage, which may result in full reproductive integrity of  
the cells (i.e. development of  resistance). 2 TIC .... values 
< 0 indicate cytocidal drug action. 
Figure 1 shows the effect of  cisplatin on the N IH:OV-  
CAR-3 cell line. At the lowest concentration (0.1 gM) the 
cells are weakly inhibited initially but fully recover after 
about 200 h drug exposure. This behavior can be ex- 
plained by a resistance of  the cell line against cisplatin, 
which is described by Hamilton et al. (1983). At higher 
(therapeutically non-relevant) concentrations clear-cut 
dose-dependent inhibition is observed. Compared to cis- 
platin for both DL-3-PtCI2 (Fig. 2) and meso-3-PtCl2 
(Fig. 3) higher doses are required to achieve quiactive in- 
hibition. Whereas DL-3-PtC12 is cytocidal at 2.5 gM and 
5.0 gM, meso-3-PtC12 exhibits a cytocidal effect only in 
its highest concentration (5 gM). In contrast to DL-3- 
PtC12 the onset of  action of  meso-3-PtC12 is delayed. Al- 
though the equiactive in vitro concentrations of the most 
active diastereoisomer DL-3-PtC12 are higher than those 
of  cisplatin, there may be an advantage with this com- 
pound in the therapy of  ovarian cancer owing to its mark- 
edly lower toxicity (i.e. the realization of  cytocidal but 
non-toxic drug concentrations under in vivo condi- 
tions). 3 Therefore, DL-3-PtC12 could be useful for the 
first-line treatment of  ovarian cancer in combinat ion 
with cisplatin to avoid development of  resistance, as well 
as for the second-line therapy of  the cisplatin-resistant tu- 
mor. 
In the P388 leukemia experiments in vivo DL-3-PtC12 
proved to be very active (Table 6). In contrast, meso-3- 
PtC12 showed only marginal ant i tumor effects even at the 
highest olerated ose. DL-3-PtCI2 is also much better tol- 
erated than meso-3-PtC12. DL-3-PtC12 (30 tamol/kg) has a 
better effect if it is applied in nine doses (days 1-9; T/C= 
205%) instead of  three doses (days 1, 5, 9; T/C= 170%). 
The effect OfDL-3-PtC12 is comparable to that of  cisplatin 
(dose: 3 x 5 ~tmol/kg, days 1, 5, 9; TIC." DL-3-PtC1/ = 
170%; cisplatin = 180%). However, DL-3-PtC12 is much 
less toxic than cisplatin. The dosage 9 x 13.2 gmol/kg DL- 
3-PtCl2 produced the strongest ant i tumor effect (TIC = 
300%). At the end of  the experiment (day 30) four out of  
six animals survived. After a further increase of  dose, 
toxic side-effects became evident, which demanded a re- 
duction of  the number of  doses from nine to five. 
In further experiments the activities of  meso-3-PtC12 
and DL-3-PtC12 in wild-type (ETwa-) and cisplatin-resist- 
ant (ETvDv). Ehrlich ascites tumor were studied. These 
results are demonstrated in Figs. 4 6. In the case of  com- 
plex meso-3-PtC12 (Fig. 4) three daily doses of  5 mg/kg 
were curative and three of  10 mg/kg were already lethal 
Table 5. Antitumor effect of R,S and R,R/S,S [t,2-bis(2-hydroxy- 
phenyl)ethylenediamine]dichloroplatinum(II) on the hormone- 
independent, human MDA-MB231 breast cancer cell line 
Compound [3H] Incorpo- Inhibition EDso 
Thymidine ration of cell 
inhibition EDs0 growth at 
at 5 gM 5 p,M 
(%) (~tM) (%) (~tM) 
Cisplatin 97.6 0.16 83.9 0.56 
DL-3-PtC12 95.3 0.60 85.7 1.5 
meso-3-PtC12 59.9 3.7 43.7 6.6 
2 The development ofresistance can also be feigned by the decom- 
position of the drug under the cell culture conditions used. This 
can happen particularly with highly reactive compounds like cis- 
platin, which exchanges its chlorine substituents for anionic om- 
ponents of the culture medium 
s The evaluation of DL-3-PtC12 on the P388 leukemia of the mouse 
proves that single doses of 40 gmol/kg are tolerated by the ani- 
mals without complications (See also Table 6: animal weight 
change days 1-5). Therefore it is supposed that under in vivo con- 
ditions in ovarian cancer cytocidal DL-3-PtCI2 levels (> 2.5 gmol/ 
kg) are achievable. This is especially true for intraperitoneal and 
intrapleural dministration, meso-3-PtClz is a less promising drug 
because of its lower antitumor activity and its higher toxicity 
(compare Table 6) 
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Fig. 1 A, B. Effect of cisplatin on the proliferation of NIH:OVCAR- 
3 ovarian cancer cells. A Growth curves. B Plot of corrected TIC 
values versus time of drug exposure, where T is absorbance of 
treated cells and C is that of the controls, z~, 0.1 laM; o, 1 pM; rq, 
5 pM; e, absorbance of the dimethylformamide control with the 
curve fitted (Reile et al. 1989) 
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Fig. 2 A, B. Effect of DL-3-PtC12 on NIH:OVCAR-3 cells. A Growth 
curves. B Corrected TIC values as a function of time of incubation. 
zx, 1.0 pM; o, 2.5 gM; n, 5.0 p.M; , computed control 
Table 6. Antitumor effect of R,S and 
R,R/S,S [1,2-bis(2-hydroxyphenyl)ethylene- 
diamine]dichloroplatinum(II) on the P388 
leukemia of the CD2F 1 mouse 
a The compounds were administered intra- 
peritonally as polyethylene glycol 400/1.8 % 
NaC1 solution 
b Three of ten animals survived the end of 
the test (day 30) 
Four of six animals survived the end of 
the test (day 30) 
d Two of six animals survived the end of 
the test (day 30) 
Compound Day 
of 
injection 
Animal weight 
Single dose" Change 
days 
(pmol/kg) (mg/kg) 1-5 
Control 1, 5, 9 -1 .8  
1 9 -1 .4  
Cisplatin 1, 5, 9 5 1.5 1.4 
DL-3-PtC12 1, 5, 9 40 20.4 --0.4 
1, 5, 9 20 10.2 --0.4 
1, 5, 9 10 5.1 --1.0 
1, 5, 9 5 2.55 --0.7 
1 9 3.3 1.68 - -2 .1  
1-9 1.7 0.87 1.2 
Control 1-9 -- 0.5 
Cisplatin 1-6 3.3 1.0 3.4 
DL-3-PtC1 z 1-9 6.6 3.4 0.0 
1-9 13.2 6.8 2.5 
1-5 26.4 12.6 4.4 
meso-3-PtCl2 1, 5, 9 40 20.4 
1, 5, 9 20 10.2 4.0 
1, 5, 9 10 5.1 --0.3 
1-9 6.6 3.37 0.4 
1-9 3.3 1.68 1.5 
Median survival TIC 
time (range) (%) 
(days) 
10 (10-12) 100 
10 (9-11) 100 
18 (16-21) 180 
22.5 (17-25) 225 
17 (16-18) 170 
17 (17-19) 170 
17 (17-25) 170 
20.5 (17-25) 205 
16 (16-18) 160 
10 (9-11) 100 
20 (9-30) b 200 
21 (20-25) 210 
30 (24~30) c 300 
28 (8-30) a 280 
Toxic 
13.5 (6 16) 135 
11 (10-13) 111 
14 (10-14) 140 
12.5 (1~19) 125 
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Fig. 3A, B. Effect of meso-3-PtCl2 on NIH:OVCAR-3 cells. 
A Growth curves. B Corrected T/C values as a function of time of 
incubation. A 1 pM; o 2.5 pM; [] 5 pM; - -  computed control 
in the wild-type tumor. For complex DL-3-PtC12 the thera- 
peutic ratio was improved in the wild-type tumor: as 
shown in Fig. 5 a dose range of 3 x 5 mg/kg to 3 x 10 mg/ 
kg was curative without any significant oxicity (compare 
also Table 6). The most important result of this study is 
demonstrated in Fig. 6. When both complexes meso-3- 
PtC12 and DL-3-PtC12 were tested in the cisplatin-resist- 
ant subline in vivo, 70% of the tumor-bearing animals 
could be cured by complex DL-3-PtC12 as compared to 
only 20% of the animals when treated with complex 
meso-3-PtC12. This result was substantiated by a repeat 
experiment and is based on the documentation of in vivo 
activity in 20 animals altogether. 
The lack of complete cross-resistance of DL-3-PtC12 
with cisplafin, found in the comparative testing on a cis- 
platin-sensitive and -resistant Ehrlich ascites tumor of the 
mouse, was also observed on the L1210 leukemia cell line. 
In these experiments, DL-3-PtC12 proved to be markedly 
more active than cisplatin on the cisplatin-sensitive 
L1210 cell line as well as on the cisplatin-resistant (25- 
fold) L1210 subline (Fig. 7). meso-3-PtC12 was compar- 
ably active with cisplatin on the sensitive L1210 cell line 
and inactive on the resistant L1210 subline (Fig. 7). 
DL-3-PtC12 was also tested against a series of resistant 
L1210 cell lines developed by Eastman et al. (1987). Only 
little cross-resistance was found against the L1210/DDP 5 
and L1210/DDPlo cells (DDP = cisplatin), which are 
highly resistant against cisplafin (Table 7). It is of further 
243 
100 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
50 
10 20 30 DAYS 
CONTROL 
- - - 3 x 5 mg/kg  meso-3 -P tC l  2 .  days  1,2,3 
..... 3 x 10 mg/kg n~so-3-PtCl 2. 
Fig. 4. Effect of the platinum complex meso-3-PtC12 on the cisplatin- 
sensitive Ehrlich ascites tumor of the mouse 
J loo ============================================= 
50 
g 
i 0  20 30 BAYS 
CONTROL 
- - 3 X 5 mg/kg D .L -3 -P tC I2 ,  Doys 1 ,2 ,5  
. - 3 x lO mg/kg D,L-3-PtCI 2 
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Fig. 6. Effect of the platinum complexes meso-3-PtC12 and DL-3- 
PtC12 on the cisplatin-resistant Ehrlich ascites tumor of the mouse 
-5 
:> 
> 
I_ 
D 
i f )  
0.1- 
0.01 
LI210/DDP L1210/WT 
I0 20 30 40 ~176176 o Co ~o ~o 2~o 
Dose IpMI 
Fig. 7. Cytotoxic activity of cisplatin (DDP/O), mese-3-PtClz (tl) 
and DL-3-PtC12 (A) on the cisplatin-sensitive (L1210/WT) and on the 
cisplatin-resistant (L1210/DDP) LI210 leukemia cell line 
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Table 7. Growth-inhibiting effect of DL- 
[1,2-bis(2-hydroxyphenyl)ethylenediamine]- 
dichloroplatinum(II) on various L1210 
leukemia cell lines (numbers in 
paranthesis are-fold resistance) 
Compound EDs0 (gM) 
L1210/0 L1210/DDP5 L1210/DDP10 L1210/DACH 
Cisplatin 0.3 17 (55) 32 (107) 13 (4) 
DL-3-PtCI 2 3.7 13 (3) 24 (6) 17 (4.6) 
interest that the L1210/DACH cells, which are 40-fold re- 
sistant o (1,2-diaminocyclohexane)dichloroplatinum(II)  
(DACH),  also showed only marginal resistance to DL-3- 
PtC12. 
Owing to its low toxicity a and its ant i tumor effect on 
various models described here, DL-3-PtC12 is of great in- 
terest for further development. The effect on the NIH:  
OVCAR-3 ovarian cancer cell line makes this type of 
compound a promising candidate for use in the therapy 
of ovarian cancer. In further publications we will report 
on attempts to optimize DL-3-PtC12 . 
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